Direkt zum Inhalt
Merck
  • Colonic necrosis in a young patient receiving oral kayexalate in sorbitol: case report and literature review.

Colonic necrosis in a young patient receiving oral kayexalate in sorbitol: case report and literature review.

The Kaohsiung journal of medical sciences (2011-04-06)
Yueh-Hung Chou, Hsin-Yi Wang, Min-Shu Hsieh
ZUSAMMENFASSUNG

Kayexalate (sodium polystyrene sulfonate) is a cation-exchange resin used to treat patients with hyperkalemia. Concomitant administration of kayexalate and sorbitol may induce gastrointestinal injury, which is potentially lethal. However, this well-documented complication is often underrecognized both clinically and pathologically. We propose a typical case along with colonoscopic photos and microscopic pictures. Additionally, we also present a review of the literature on this rare drug-induced side effect.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
D-Sorbit, ≥98% (GC)
Sigma-Aldrich
D-Sorbit, BioUltra, ≥99.0% (HPLC)
Sigma-Aldrich
D-Sorbit, 99% (GC)
Sigma-Aldrich
D-Sorbit, ≥98% (GC), for molecular biology
USP
Sorbit, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
D-Sorbit, ≥98% (GC), BioReagent, suitable for cell culture, suitable for plant cell culture
Sigma-Aldrich
Sorbit F -Lösung, 70 wt. % in H2O, Contains mainly D-sorbitol with lesser amounts of other hydrogenated oligosaccharides
Sigma-Aldrich
D-Sorbit, FCC, FG
Supelco
Sorbit, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D-Sorbit, ≥98% (GC), BioXtra
Sorbit, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
D-Sorbit, liquid, tested according to Ph. Eur.